Streetbeat News

Revenues

RL

Eight financial analysts have recently updated their ratings for Ralph Lauren (NYSE:RL), with a mix of bullish and indifferent stances. The average 12-month price target has been raised to $144.25, up 8.3% from the previous $133.20. Analysts from firms like Raymond James, Wells Fargo, Goldman Sachs, TD Cowen, UBS, Telsey Advisory Group, and Evercore ISI Group have raised their price targets, indicating a positive outlook on the company's performance. Ralph Lauren's financials show a positive revenue trend, a high net margin, and strong ROE and ROA, with a prudent debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 3:00 pm

TPR

Analysts have mixed views on Tapestry (NYSE:TPR), with 9 ratings ranging from bullish to bearish. The average 12-month price target is $40.56, down from $47.29. Actions by analysts include both raised and lowered ratings and price targets. Tapestry, owning brands like Coach, Kate Spade, and Stuart Weitzman, has shown positive revenue growth and strong financial health indicators. The company plans to acquire Capri, adding brands like Michael Kors, Versace, and Jimmy Choo.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 3:00 pm

NBY

NovaBay Pharmaceuticals has reported a significant 64% year-over-year growth in subscription-based sales for its Avenova unit. The company also saw a 38% increase in subscription-based customers in 2023 compared to the previous year. Avenova's online sales from subscribers constituted 24% of the total in 2023, a notable rise from 14% in 2022. The product has received positive feedback, with an average 4.5-star rating from over 13,000 customer reviews across various online platforms.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 2:30 pm

SSBI

Summit State Bank reported a decrease in earnings per share (EPS) for Q4 to $0.28, down from $0.68 year-over-year (YoY). Revenue also declined to $15.333 million from $16.320 million YoY.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 2:23 pm

HITI

High Tide Inc. (NASDAQ:HITI) reported a 37% year-over-year revenue growth for 2023, with total revenue reaching CA$487.7 million. The company also saw a 40% quarter-over-quarter increase in free cash flow in Q4, and a reduction in net loss from CA$52.5 million in Q4 2022 to CA$31.8 million in Q4 2023. Adjusted EBITDA for the year was up 110% compared to 2022. After the announcement, HITI shares traded 2.59% higher at $1.98 per share after hours.

Portfolio Pulse from Jelena Martinovic

January 30, 2024 | 2:13 pm

FFIN

First Finl Bankshares (NASDAQ:FFIN) has been the subject of diverse analyst ratings over the past three months, with 4 indifferent ratings in total and 1 in the last 30 days. Analysts have raised their 12-month price targets, with an average of $32.25, reflecting a 9.32% increase from the previous $29.50. The company operates in community banking in Texas and has shown a -2.08% revenue decline as of December 31, 2023, but outperforms industry averages in net margin, ROE, and ROA, and has a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 2:01 pm

C

Nine analysts have recently updated their ratings on Citigroup (NYSE:C), with a mix of bullish and indifferent stances. The average 12-month price target is now $64.44, up from $59.00, with a high estimate of $93.00 and a low of $47.00. Analysts from firms including Morgan Stanley, Oppenheimer, Piper Sandler, HSBC, Wolfe Research, Barclays, and Goldman Sachs have raised their price targets. Citigroup's financial performance shows challenges with negative revenue trends, below-average net margin, ROE, and ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 2:01 pm

MPW

Analysts have recently updated their ratings and price targets for Medical Properties Trust (NYSE:MPW), with a new average price target of $4.62, representing a 52.22% decrease from the previous target of $9.67. The ratings range from 'Sell' to 'Hold', with price targets varying from $2.00 to $7.00. The company's financial health shows a revenue decline of -12.99% over the past 3 months, a high net margin of 37.97%, and a strong ROE of 1.4%. Medical Properties Trust is a healthcare facility REIT with a lower market capitalization compared to industry averages and is considered for mergers and acquisitions as part of its growth strategy.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 2:00 pm

EPAM

Seven analysts have updated their ratings on EPAM Systems (NYSE:EPAM) in the last three months, with a mix of bullish and bearish sentiments. The average 12-month price target is now $295.14, up 19.39% from the previous target of $247.20. Analysts from firms including Mizuho, Morgan Stanley, Citigroup, Jefferies, and Piper Sandler have made various adjustments to their ratings and price targets. EPAM's financials show a negative revenue trend with a -6.1% growth, a strong net margin of 8.44%, a below-average ROE of 2.96%, an exceptional ROA of 2.35%, and a low debt-to-equity ratio of 0.05.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 2:00 pm

NPCE

NeuroPace (NASDAQ:NPCE) has been analyzed by 6 analysts, showing a mix of bullish to indifferent sentiments. The average 12-month price target is $11.83, a significant increase from the previous $8.00. Analysts from firms like Leerink Partners, Lake Street, Morgan Stanley, Cantor Fitzgerald, and JP Morgan have provided ratings and adjusted price targets. NeuroPace is a medical device company focusing on epilepsy treatments, with recent revenue growth of 47.23% and a market cap below industry average. The company has a high debt-to-equity ratio of 4.38, and its ROE and ROA are below industry standards.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 2:00 pm